3 documents found, page 1 of 1
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The ...
Sousa-Pinto, Bernardo; Schünemann, Holger J.; Sá-Sousa, Ana; Vieira, Rafael José; Amaral, Rita; Anto, Josep M.; Klimek, Ludger; Czarlewski, WienczyslawaIntroduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air ®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air ® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air ® data, assessing the weeks fo...
Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: ...
Bousquet, Jean; Anto, Josep M; Sousa-Pinto, Bernardo; Czarlewski, Wienczyslawa; Bedbrook, Anna; Haahtela, Tari; Klimek, Ludger; Pfaar, OliverMASK-air® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Econo...
Patient-centered digital biomarkers for allergic respiratory diseases and asthm...
Bousquet, Jean; Shamji, Mohamed H.; Anto, Josep M.; Schünemann, Holger J.; Canonica, G. Walter; Jutel, Marek; Del Giacco, Stefano; Zuberbier, TorstenBiomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mH...